GlobalData Healthcare

Image credit: Shutterstock/Drazen Zigic On 18 October, at the 128th Annual Meeting of the American Academy of Ophthalmology (AAO) 2024 in Chicago, clinical trial results were presented for the Phase II trial of EyePoint’s EYP-1901 (vorolanib) (DAVIO 2; NCT05381948), investigating […]

The opioid addiction market across the eight major markets (8MM: Australia, Canada, France, Germany, Italy, Spain, the UK and the US) is poised to grow at a compound annual growth rate (CAGR) of 1.8% from $2 billion in 2023 to

A potential three-year framework agreement between the Greek government and the pharmaceutical industry, starting at the beginning of 2025, has been the focus of recent discussions between the Ministry of Health (MoH) and associations representing the pharmaceutical industry in Greece.

The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is set to grow from sales of $11.5bn in 2023 to $30.8bn in 2033. The recent approvals of Sanofi/Regeneron’s

Psoriasis is an autoimmune skin condition that causes a rash with itchiness and discomfort. The most common type of psoriasis is plaque, which causes dry, itchy skin patches covered in scales. Treatments are available to manage symptoms, but there is no

According to the most recent European Health Interview Survey for 2019 to 2020, allergy is the most common chronic health condition in the UK, affecting 30.4% of men and 36.0% of women. One major example is food allergies, which occur

In China, type 2 diabetes has become an increasingly prevalent, serious public health challenge. But despite the growing challenge, relatively little scholarship has explored the epidemiology of type 2 diabetes among the country’s children. In a recent publication in The

Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals have seen an 800% growth in total licensing agreement deal values from 2019 to 2024YTD, according to GlobalData’s Pharma Intelligence Center Deals Database. mRNA-based vaccines, which work by instructing cells to produce specific proteins

The first needle-free epinephrine nasal spray, Neffy by ARS Pharmaceuticals, represents a significant breakthrough in emergency treatment for type I allergic reactions, including anaphylaxis, which disproportionately affects asthma patients. Neffy’s unique delivery system provides an alternative to traditional injectable devices

The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market. The asset is tailored towards patients with moderate-to-severe exacerbations with chronic obstructive pulmonary disease